Healthcare Global Enterprises Limited Q2FY26 Concall Decoded: Cancer Is Growing Faster Than India’s GDP—and HCG Is Ready to Monetise It
1. Opening Hook
While India debates healthcare affordability and private hospitals argue margins versus morality, HCG calmly drops a statistic that should make multispecialty CEOs uncomfortable—mortality at 0.9%, nearly one-third of peers. No chest-thumping, no buzzwords, just a blunt reminder that focus beats sprawl.
This wasn’t a quarter about beds and buildings. It was a strategy-heavy, long-horizon concall where management basically said: cancer is underdiagnosed, underpenetrated, and structurally undersupplied—and we plan to own that gap.
With KKR in the driver’s seat, capex discipline back in fashion, and ROCE finally allowed to speak louder than expansion vanity, HCG sounds less like a hospital chain and more like a compounding healthcare platform.
Stick around—because this wasn’t about next quarter’s EBITDA. It was about who controls oncology economics for the next decade.
2. At a Glance
Revenue CAGR ~15% (5Y) – Slow by hype standards, lethal by compounding math.
EBITDA CAGR ~18% (5Y) – Scale finally behaving like scale.
Gross mortality 0.9% – Outcomes doing the marketing job.
Net debt/EBITDA down to 2.3x – Banks no longer sleeping in ICU.
Capacity utilisation ~55% – Growth hiding in plain sight.
3. Management’s Key Commentary (Decoded)
“Specialist focus leads to better outcomes and stronger economics.” (Translation: Multispecialty hospitals dilute both.) 😏
“India has only 0.3 LINACs per million population.” (Translation: Supply shortage = pricing power.)
“We operate at 50–60% of revenue potential.” (Translation: Same hospitals, more money—no land drama.)
“Our mature centres deliver 27% ROCE.” (Translation: This model works when patience exists.)
“70–75% of future growth will come from existing centres.” (Translation: Brownfield is sexier than greenfield.)
“Milann strategic options are being evaluated.” (Translation: Fertility may get discharged.) 😏
